Patients with advanced melanoma achieved deep and durable responses after receiving the tumor-infiltrating lymphocyte (TIL) therapy lifileucel alongside the immune checkpoint inhibitor pembrolizumab as a first-line treatment, according to results from a new clinical trial. Approximately two-thirds (62.5%) of patients saw their tumors shrink significantly, with many experiencing substantial and long-lasting responses to the combined treatment.

Sacituzumab tirumotecan extended both progression-free and overall survival compared with standard chemotherapy in patients with advanced or recurrent endometrial cancer, according to findings from the phase III TroFuse-005/ENGOT-en23/GOG-3095 trial presented at the ESMO Congress 2026 (Abstract LBA11). A report of the findings was also simultaneously published in The Lancet. 

Breast cancer screening with digital breast tomosynthesis plus synthesized two-dimensional mammography resulted in fewer invasive interval breast cancers over 2 years than standard digital mammography, although the difference did not reach statistical significance. Weigel et al reported the 24-month follow-up results of the randomized TOSYMA trial in The Lancet Oncology.

I have had many idols in medicine. Many eventually let me down. Claudia Henschke, PhD, MD, Professor of Radiology and Head of the Lung and Cardiac Screening Program at Mount Sinai Medical Center in New York City, an expert in diagnostic radiology, and a pioneer in computed tomography (CT) screening for early lung cancer, never let me down.